-
Detailed Analysis
Download Detailed Report Add to Watchlist
Values as of: 2021-01-20
Values as of: 2021-01-20
DELISTED - ArthroCare Corporation (ArthroCare), is a medical device company. ArthroCare develops and manufactures surgical devices, instruments, and implants. Its devices enable surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its Coblation technology. This technology dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology, including its OPUS line of fixation products, as well as re-usable surgical instruments. ArthroCare's two core product consists of sports medicine and ear, nose, and throat (ENT), as well as other areas, such as spine, wound care, urology and gynecology. It's Sports Medicine, ENT and other products are marketed and sold through two principal geographic distribution channels: Americas (North and South America) and International (all other geographies). In July 2013, ArthroCare Corp completed the acquisition of ENTrigue Surgical, Inc.
Company Website : http://www.arthrocare.com
Address : 7000 West William Cannon Drive, Building 1 78735,Austin,USA
Fiscal Year End : December
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
LGCY | Legacy Reserves Inc |
N/A |
USD61,525,874.67B | 1.10 | 5.30 |
FTD | FTD Companies, Inc |
N/A |
USD28,725,913.80B | N/A | N/A |
KEYW | The KeyW Holding Corporation |
N/A |
USD24,651,104.38B | 166.80 | 24.48 |
SNHY | Helios Technologies, Inc |
N/A |
USD17,848,852.22B | 1,000,000.00 | N/A |
QTNA | Quantenna Communications, Inc |
N/A |
USD8,997,243.52B | 175.07 | 79.98 |
INSY | INSYS Therapeutics, Inc |
N/A |
USD4,995,459.82B | 115.90 | N/A |
CHKE | Apex Global Brands Inc |
N/A |
USD384,202.91B | 17.30 | N/A |
AMCN | AirNet Technology Inc |
N/A |
USD308,457.30B | 1.00 | N/A |
PDVW | pdvWireless, Inc |
N/A |
USD95,944.74B | N/A | N/A |
AIPT | Predictive Oncology Inc |
N/A |
USD38,513.36B | N/A | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | -52.85% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -52.85% | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -5.19% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -5.19% | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 15.69% | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | -33.06% | N/A | N/A | N/A | N/A | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | N/A | N/A | N/A | N/A | N/A | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | 14.04% | N/A | N/A | N/A | N/A | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | N/A | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
There is nothing we particularly dislike